Diamel Therapy in Polycystic Ovary Syndrome Reduces Hyperinsulinaemia, Insulin Resistance, and Hyperandrogenaemia

Table 5

Evolution of the insulin resistance index (HOMA-IR) in patients with the polycystic ovary syndrome.

	n	Diamel	n	Placebo
HOMA-IR start	18	4.3± 2.4*	19	4.6±2.5
HOMA-IR 3 months	17	2.6±1.3	16	3.3±2.0
HOMA-IR 6 months	16	2.4±1.2 *	16	3.3±2.1

* 𝑃=0.04.
Values are means ± SD.